SLC9A1 and endometrial cancer: LEFTY2 is partially effective by down-regulating Na+/H+ exchanger 1 (NHE-1), leading to a decrease of glycolytic flux (the rate at which molecules proceed through the glycolytic pathway) in endometrial cancer cells [31].